Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.311 95% CI 0.257–0.375Authors' conclusion
Tirzepatide demonstrated superior clinical outcomes compared with BMS in adults with obesity, including significant reductions in all-cause mortality, MACEs and MAKEs. These findings suggest that tirzepatide may serve as an effective non-surgical alternative to BMS, with broad applicability across diverse patient populations.
Study context
- Population
- Adults with obesity (body mass index (BMI) ≥ 30 kg/m²), TriNetX network84,884 matched pairs
- Exposure
- Tirzepatide vs bariatric metabolic surgery (BMS)
- Outcome
- All-cause mortality
Methodological detailsmulti-institutional, propensity score-matched (1:1), TriNetX network
- Multi-institutional
- Propensity score-matched (1:1)
- TriNetX network
Main finding
As reported in the abstract
Hazard ratio
0.311
95% CI 0.257–0.375
P < 0.0001
By group
Tirzepatide
0.19 per 100 person-years
BMS
0.57
per 100 person-years
Tirzepatidevs BMS
HR 0.311 (95% CI 0.257–0.375); P < 0.0001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| MACE | 0.743 (0.673–0.821) | P < 0.0001 | |
| Major adverse kidney events (MAKEs) | 0.375 (0.336–0.419) | P < 0.0001 | |
| 0.20.5125Hazard ratio (log scale) |
All-cause mortality by age, sex and BMI subgroups
- Mortality benefits consistent across age groups, genders and BMI categories
- Significant reductions in primary and secondary outcomes across most categories
Original publication
Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study. Diabetes Obes Metab. Published 20 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →